middle.news
Telix Surpasses US$1 Billion Revenue Forecast as Clinical Trials Advance
8:26am on Tuesday 21st of July, 2026 AEST
•
Healthcare
Read Story
Telix Surpasses US$1 Billion Revenue Forecast as Clinical Trials Advance
8:26am on Tuesday 21st of July, 2026 AEST
Key Points
Q2 revenue rises 21% year-on-year to US$247 million
Precision Medicine sales up 30% year-on-year
FDA clears Part 2 of ProstACT Phase 3 trial for TLX591-Tx
Strategic collaboration with Regeneron nets US$40 million upfront
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Telix Pharmaceuticals (ASX:TLX)
OPEN ARTICLE